Tirzepatide at 15mg produces **22.5%** weight loss compared to **16.3%** for semaglutide at 2.4mg. That's a 6.2 percentage point difference that translates to real pounds. For someone at 220 lbs, it means 13 extra pounds lost with tirzepatide. (Ciudin et al., Advances in Therapy, March 2026. PMID: 41820778)
The analysis looked at obesity trials in people without diabetes. No bariatric surgery studies. No diabetic populations. Just straightforward weight loss data across the three major drugs.
the numbers by drug and dose
Tirzepatide 15mg: **22.5%** average weight loss. Tirzepatide 10mg: **19.5%** average weight loss. Semaglutide 2.4mg: **16.3%** average weight loss. Liraglutide 3mg: **8.4%** average weight loss.
Even at the lower dose, tirzepatide 10mg still beats semaglutide's maximum dose by 3.2 percentage points. That's the dual-receptor advantage showing up in the data.
why tirzepatide wins
Tirzepatide hits two targets instead of one. It activates GLP-1 receptors like semaglutide does, but it also activates GIP receptors. GIP stands for glucose-dependent insulinotropic polypeptide, which is a mouthful that basically means "another hormone that helps with metabolism."
That second pathway gives tirzepatide extra leverage on appetite, blood sugar, and fat storage. More targets means more ways to lose weight.
the dropout problem
Higher doses work better but make more people quit. Tirzepatide 15mg had about **15%** of people stop taking it due to nausea, vomiting, or other gut issues. Semaglutide 2.4mg dropped that to **7%**.
The 10mg tirzepatide dose hits a middle ground. Still outperforms semaglutide but with fewer people bailing out from side effects. For many patients, that's the sweet spot.
what this analysis can't tell you
These weren't head-to-head trials. The researchers combined separate studies using statistical techniques called network meta-analysis. It's useful but not as clean as having all the drugs tested in the same trial.
The studies also used brand-name versions (Mounjaro, Zepbound, Wegovy). Compounded versions might behave differently. There's no data here to predict how well compounded tirzepatide performs compared to compounded semaglutide.
Trial durations varied too. Some studies ran 12 weeks, others went 68 weeks. That's a huge range, and pooling them together introduces noise into the results.
switching between drugs
If you're on semaglutide and hitting a plateau, tirzepatide might push you further. The 10mg dose shows clear advantages over maximum semaglutide with reasonable tolerability.
If you're already struggling with nausea on semaglutide, jumping to tirzepatide 15mg probably isn't smart. Start with 10mg or stick with what works.
Insurance coverage matters too. Tirzepatide costs more than semaglutide in most situations. The extra 6 percentage points of weight loss might not be worth an extra $200 per month for everyone.
what this means for your decision
Tirzepatide clearly outperforms semaglutide on weight loss. The data is consistent across doses. But the advantage comes with more side effects and higher costs.
If maximum weight loss is the goal and you can tolerate gastrointestinal issues, tirzepatide makes sense. If you're doing well on semaglutide and losing steadily, there's no urgent reason to switch.
For detailed comparison information, see our guides on tirzepatide dosing and semaglutide protocols.
Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Peptide protocols should only be undertaken under the supervision of a qualified healthcare provider. Individual results may vary, and all medications carry potential risks and side effects.